ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - fusidatna kiselina hemihidrat, betametazonvalerat - krema - 20 mg/g + 1 mg/g - urbroj: 1 g kreme sadrži 20,4 mg fusidatne kiseline 0,5 h2o (ekvivalentno 20 mg fusidatne kiseline) i 1,214 mg betametazonvalerata (ekvivalentno 1 mg betametazona)

বসনিয়া ও হার্জেগোভিনা - ক্রোয়েশীয় - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

unifarm d.o.o. lukavac - diflukortolon, izokonazol - krema - 10 mg/1 g+ 1 mg/1 g - 1 g kreme sadrži 10 mg izokonazol nitrata i 1 mg diflukortolona (u obliku diflukortolon valerata)

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dechra veterinary products a/s, mekuvuj 9, 7171 uldum, danska - fusidatna kiselina; betametazon (u obliku valerata) - gel - kortikosteroidi, kombinacije s antibioticima - pasa

ক্রোয়েশিয়া - ক্রোয়েশীয় - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

intervet international bv - podružnica u rh, ivana lučića 2a, 10000 zagreb, republika hrvatska - gentamicin u obliku gentamicinsulfata ; betametazon u obliku betametazonvalerata; klotrimazol - kapi za uho, suspenzija - pasa

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

pharma mar s.a. - trabectedin - ovarian neoplasms; sarcoma - antineoplastična sredstva - yondelis je indiciran za liječenje bolesnika s naprednim sarkom mekog tkiva, nakon neuspjeha anatraciklinima, i ili nezgodan za primanje tih agenata su. podaci o učinkovitosti temelje se uglavnom na bolesnika s liposarkom i leiomyosarcomom. Йонделис u kombinaciji s пегилированным липосомальным doksorubicin (fpga) indiciran za liječenje pacijenata s relaps платино osjetljivi raka jajnika .

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, metformin hidroklorid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

gedeon richter plc. - norelgestromin, ethinyl estradiol - kontracepcija - spolni hormoni i modulatori genitalnog sustava, - Ženska kontracepcija. evra je namijenjen za žene u fertilnoj dobi. sigurnost i efikasnost je instaliran kod žena u dobi od 18 do 45 godina.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

takeda pharma a/s - метформина hidroklorid пиоглитазона hidroklorid - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - glubrava je indicirana kao druga linija liječenja tipa 2 šećerne bolesti u odraslih bolesnika, osobito prekomjernom tjelesnom težinom, koji ne mogu postići zadovoljavajuću kontrolu glikemije u maksimalno podnošljivoj dozi peroralnim metforminom. nakon početka terapije s пиоглитазоном, pacijenti moraju biti revidiran nakon tri do šest mjeseci, za procjenu adekvatnosti odgovora na liječenje (e. smanjenje pokazatelja hba1c). kod bolesnika koji ne pokazuju adekvatan odgovor treba da se ukine pioglitazone. u svjetlu potencijalnih rizika za dugotrajno liječenje, propisane lijekove treba potvrditi u kasnijim rutinske inspekcije da dobro pioglitazone sprema.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).